HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Papers In Press, published online ahead of print March 1, 2006
J. Lipid Res., doi:10.1194/jlr.M500349-JLR200

This Article Full Text Full Text (PDF) HTML Page - index.htslp All Versions of this Article: M500349-JLR200v1 47/3/537    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clark, R. W. Articles by Bamberger, M. J. Search for Related Content PubMed PubMed Citation Articles by Clark, R. W. Articles by Bamberger, M. J. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 47, 537-552, March 2006
Copyright © 2006 by American Society for Biochemistry and Molecular Biology

Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action

Ronald W. Clark^1,*, Roger B. Ruggeri^*, David Cunningham and Mark J. Bamberger^*

^* Department of Metabolic Diseases, Pfizer Global Research and Development, Groton, CT
Department of Protein Chemistry and Fermentation, Pfizer Global Research and Development, Groton, CT

The online version of this article (available at http://www.jlr.org) contains additional three figures.

Published, JLR Papers in Press, December 2, 2005.

¹ To whom correspondence should be addressed. e-mail: ronald.w.clark{at}pfizer.com

We have identified a series of potent cholesteryl ester transfer protein (CETP) inhibitors, one member of which, torcetrapib, is undergoing phase 3 clinical trials. In this report, we demonstrate that these inhibitors bind specifically to CETP with 1:1 stoichiometry and block both neutral lipid and phospholipid (PL) transfer activities. CETP preincubated with inhibitor subsequently bound both cholesteryl ester and PL normally; however, binding of triglyceride (TG) appeared partially reduced. Inhibition by torcetrapib could be reversed by titration with both native and synthetic lipid substrates, especially TG-rich substrates, and occurred to an equal extent after long or short preincubations. The reversal of TG transfer inhibition using substrates containing TG as the only neutral lipid was noncompetitive, suggesting that the effect on TG binding was indirect. Analysis of the CETP distribution in plasma demonstrated increased binding to HDL in the presence of inhibitor. Furthermore, the degree to which plasma CETP shifted from a free to an HDL-bound state was tightly correlated to the percentage inhibition of CE transfer activity. The finding by surface plasmon resonance that torcetrapib increases the affinity of CETP for HDL by 5-fold likely represents a shift to a binding state that is nonpermissive for lipid transfer. In summary, these data are consistent with a mechanism whereby this series of inhibitors block all of the major lipid transfer functions of plasma CETP by inducing a nonproductive complex between the transfer protein and HDL.

Supplementary key words lipid transfer • high density lipoprotein • atherosclerosis • cardiovascular disease

Abbreviations: apoA-I, apolipoprotein A-I BPI, bactericidal/permeability-increasing protein; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; FC, free cholesterol; FPLC, fast-protein liquid chromatography; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; Mr, apparent molecular weight; PC, phosphatidylcholine; PL, phospholipid; PLTP, phospholipid transfer protein; SPR, surface plasmon resonance; TC, total cholesterol; TG, triglyceride; WT, wild-type

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				X. Hu, J. D. Dietz, C. Xia, D. R. Knight, W. T. Loging, A. H. Smith, H. Yuan, D. A. Perry, and J. Keiser Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition Endocrinology, May 1, 2009; 150(5): 2211 - 2219. [Abstract] [Full Text] [PDF]

				M. Vergeer, M. L. Bots, S. I. van Leuven, D. C. Basart, E. J. Sijbrands, G. W. Evans, D. E. Grobbee, F. L. Visseren, A. F. Stalenhoef, E. S. Stroes, et al. Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity: A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials Circulation, December 9, 2008; 118(24): 2515 - 2522. [Abstract] [Full Text] [PDF]

				D. Dalvie, W. Chen, C. Zhang, A. D. Vaz, T. A. Smolarek, L. M. Cox, J. Lin, and R. S. Obach Pharmacokinetics, Metabolism, and Excretion of Torcetrapib, a Cholesteryl Ester Transfer Protein Inhibitor, in Humans Drug Metab. Dispos., November 1, 2008; 36(11): 2185 - 2198. [Abstract] [Full Text] [PDF]

				C. Prakash, W. Chen, M. Rossulek, K. Johnson, C. Zhang, T. O'Connell, M. Potchoiba, and D. Dalvie Metabolism, Pharmacokinetics, and Excretion of a Cholesteryl Ester Transfer Protein Inhibitor, Torcetrapib, in Rats, Monkeys, and Mice: Characterization of Unusual and Novel Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and 1H Nuclear Magnetic Resonance Drug Metab. Dispos., October 1, 2008; 36(10): 2064 - 2079. [Abstract] [Full Text] [PDF]

				G. Ferns and V. Keti HDL-cholesterol modulation and its impact on the management of cardiovascular risk Ann Clin Biochem, March 1, 2008; 45(2): 122 - 128. [Abstract] [Full Text] [PDF]

				U. Tchoua, W. D'Souza, N. Mukhamedova, D. Blum, E. Niesor, J. Mizrahi, C. Maugeais, and D. Sviridov The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport Cardiovasc Res, March 1, 2008; 77(4): 732 - 739. [Abstract] [Full Text] [PDF]

				M. Guerin, W. Le Goff, E. Duchene, Z. Julia, T. Nguyen, T. Thuren, C. L. Shear, and M. J. Chapman Inhibition of CETP by Torcetrapib Attenuates the Atherogenicity of Postprandial TG-Rich Lipoproteins in Type IIB Hyperlipidemia Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 148 - 154. [Abstract] [Full Text] [PDF]

				L. A. Morehouse, E. D. Sugarman, P.-A. Bourassa, T. M. Sand, F. Zimetti, F. Gao, G. H. Rothblat, and A. J. Milici Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits J. Lipid Res., June 1, 2007; 48(6): 1263 - 1272. [Abstract] [Full Text] [PDF]